US Stock MarketDetailed Quotes

MYGN Myriad Genetics

Watchlist

14.560
-0.090-0.61%

Close Feb 14 16:00 ET

14.560
0.0000.00%

Post 18:38 ET

1.33BMarket Cap-11.38P/E (TTM)

Myriad Genetics Stock Forum

Teddy123

Feb 5 19:46

Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay

$Myriad Genetics (MYGN.US)$
Molecular Cancer Detection Breakthrough: Myriad Genetics Patents Game-Changing MRD Testing Methods

Teddy123

Feb 5 07:39

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

$Myriad Genetics (MYGN.US)$
Revolutionary Cancer Testing Integration: Myriad Genetics Slashes Result Times to Under 10 Days

905745367

Dec 6, 2024 09:01

$Myriad Genetics (MYGN.US)$ what happen to this stock?

Trytosaveabit

Mar 20, 2024 15:22

Bad sign when a patent granted gets zero attention!

$Myriad Genetics (MYGN.US)$ Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device 16 MINUTES AGO, 4:05 PM EDT VIA GLOBENEWSWIRE

Moomoo AI

Feb 1, 2024 08:31

The acquisition is expected to enable Myriad to more effectively scale and grow its tumor profiling offerings to complement its oncology portfolio of hereditary cancer and companion diagnostic testing options.

Press Release: Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory From Intermountain Precision Genomics

Moomoo AI

Jan 30, 2024 16:00

Dr. Daneker's leadership is expected to drive innovation, growth, and development of the company's oncology portfolio, including expansions into liquid biopsy and minimal residual disease testing. His experience and track record are anticipated to boost the company's strategy with health systems and large oncology practices.

Press Release: Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

Moomoo AI

Jan 18, 2024 17:37

The acquisition is set to spur innovation, growth, and further development of Myriad's oncology portfolio. It will also enhance the scaling and growth of their tumor profiling and liquid biopsy tests, including operational efficiencies, reimbursement benefits and new clinical development opportunities.

Press Release: Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory From Intermountain Precision Genomics

Moomoo AI

Jan 2, 2024 06:32

The low P/S ratio for Myriad Genetics is likely due to its subpar revenue performance and limited future growth expectations, which have suppressed its share price. These conditions could hinder a significant rise in the share price in the near future.

Investors Aren't Buying Myriad Genetics, Inc.'s (NASDAQ:MYGN) Revenues

Moomoo AI

Nov 10, 2023 13:15

Though Myriad Genetics maintains a cash surplus, doubt arises from its lack of free cash flow, negative EBIT, and significant liabilities.

Is Myriad Genetics (NASDAQ:MYGN) Using Too Much Debt?

Moomoo AI

Nov 1, 2023 08:08

CEO Paul Diaz is confident in Raha's capability to enhance profitability and expand the company, leveraging his substantial experience in diagnostics. Diaz considers Raha will introduce new ideas and expertise to progress current business missions and operational excellence.